We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
who will be holding for minimum 12 months?
not many,
too many pumpers luring in newbies then selling for them to hold.
EVG Rns wasn't that good hence Mms opened up 28% only!
it's the pumpers and traders took a different path, when in reality the path is dead end for at least 12 months.
EoA
DKE done well,
Thanks I’ll take a look x
i've also got DEST on my radar as the underlying share price is significantly disconnected with the underlying value and they are in advanced discussions for partnering deal
Exactly what I’ve at 6.32. Gla x
We opened at 7.60 - 7.80, time for a top up.
Looking to add on dips. Longterm this is going up imo.
Not selling any and looking forward to presentation tomorrow.
Finally, SFX-01 is on the cusp of realising its vast, billion dollar potential and I want to enjoy the ride through 2023. We will be multiples of today's price.
All IMHO DYOR
Happy
The traders will be buying back in again about these sort of levels. I expect an 8p+ finish today. Tomorrow should be more exciting in my opinion. Maybe 10p?
Like yesterday let the traders take there 10%
And then we should be heading north.
Only patience is required gla x
yikes, aim at its best - when is the bounce
This can be huge:
we are seeing a dose-related decrease of specific abnormal electrophysiological signal in brain regions related to social interaction, working memory and processing speed that may lead to social communication improvement, which is one of the core symptoms of autism
quick shake but nothing doing
Moving up now
Easyp, good to know :)
6.90 to sell
Up over 8% pre-open, looking good.
GLA
Jolly even if we ignore the autism potential consider what the FT says about EVG, plenty of cash and:
"The one analyst offering a 12 month price target expects Evgen Pharma PLC share price to rise to 20.00 in the next year from the last price of 7.10."
No wonder the agreement is pencilled in early..
“The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field.
The transformation in terms of company value will rerate through to the SP. Really looking forward to the investor presentation which will inevitably lead to more upside.
Let’s see what happens today.
GLA
The Earl of Aim shorting Crew has arrived
28jaczar01
Best of luck to you and well done on achieving your investment goals here.
However, I believe you are seriously underestimating the enormous promise of Stalicla's main autism candidate, which relies very heavily on Evgen's SFX-01:
https://www.businesswire.com/news/home/20220324005694/en/STALICLA-Completes-Successful-Phase-1b-Trials-for-the-First-Precision-Medicine-in-Autism-Spectrum-Disorder
As part of the deal, Stalicla will fund all future medical trials through to commercialisation. Of course, success in trials is not a foregone conclusion but there is a realistic chance that this drug could be one of the biggest advances in the treatment of autism in decades. Stalicla's team has an outstanding scientific pedigree and uses absolutely cutting edge biotech. Their endorsement is a huge boon for SFX-01.
And remember this exclusive deal is for only one indication of SFX-01. It couldn't be more exciting.
All IMHO DYOR
Happy
I was a holder since early 2021 (topping up subsequently as SP dropped into the 3s) soon after the last placing, as it seemed a good time to invest with them being cashed up. I have liked the potential of their asset, but it has always been somewhat of a disappointment to me and other LTHs that the Management has not invested significantly with their own cash in the Company shares……..why don’t those “in the know” bet on its potential ?
Yesterday news looked excellent at face value and I can understand why the SP rose significantly (although the 150% seemed well overboard). However I took a look at the Stalicla website as linked below and wasn’t impressed. These guys are a small private outfit with only 26 employees and so I would have big concerns about whether the majority of this milestone money will ever materialise for EVG.
Accordingly I decided to take advantage of the highs of the day closing price and sold out for a reasonable profit. I could have timed it wrong and it rises some more this week but the nature of the market at the moment is that it’s mainly driven by short term traders using news events to pursue price spikes and then quickly sell for profit and then move on to the next one….rinse and repeat. I will watch the action with interest during this week.
https://stalicla.com/about/team
Give it up you utter turnip.
You spend hours slating people who made money then wonder why its never you.
Comical!
who will be holding for minimum 12 months?
not many,
too many pumpers luring in newbies then selling for them to hold.
EVG Rns wasn't that good hence Mms opened up 28% only!
it's the pumpers and traders took a different path, when in reality the path is dead end for at least 12 months.
EoA
Key financial elements of the transaction
· $0.5m upfront, $0.5m on completion of the, already fully financed, Evgen-sponsored human volunteer Phase 1 study (anticipated during Q2 2023). Milestone payments up to commercial launch are $26.5m, including $5m on grant of IND by the FDA (anticipated in late 2023). Total milestones of $160.5m are payable to the Company in relation to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low to medium double-digit range in all scenarios, including on-licensing by Stalicla and use of SFX-01 in further licensed indications.